Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

[1]  T. Arneson,et al.  Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation in the United States: A Study Using a Large National Private Claims Database , 2012, Bone Marrow Transplantation.

[2]  D. Blaise,et al.  Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria , 2012, Haematologica.

[3]  R. Murphy.  Rare diseases mean big profits. , 2012, Fortune.

[4]  M. Aljurf,et al.  Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups , 2012, Haematologica.

[5]  A. Risitano,et al.  Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) , 2010, Haematologica.

[6]  S. Richards,et al.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization , 2010, Haematologica.

[7]  N. Novitzky,et al.  Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD , 2009, Bone Marrow Transplantation.

[8]  M. Mohty,et al.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. , 2008, Blood.

[9]  N. Geller,et al.  Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST). , 2007 .

[10]  H. Mandel,et al.  Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  N. Geller,et al.  Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation , 2006, British journal of haematology.

[12]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[13]  M. Sanz,et al.  Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution , 2005, Bone Marrow Transplantation.

[14]  J. P. McCoy,et al.  In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. , 2004, Blood.

[15]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[16]  M. Griesshammer,et al.  Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  E. Montserrat,et al.  The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. , 2001, Blood.

[18]  H. Esperou,et al.  Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[19]  L. Luzzatto,et al.  Bone marrow transplants for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[20]  N. Young,et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.

[21]  N. Young,et al.  Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. , 1997, Blood.

[22]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[23]  T. Miyata,et al.  Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. , 1994, The New England journal of medicine.

[24]  S. Orkin,et al.  Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. , 1985, Blood.

[25]  T. H. Ham,et al.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. , 1939, The Journal of clinical investigation.